finance.yahoo.com
Negativefinance.yahoo.com ·
altimmune shares climb first quarter 132902289
GENERAL_HEALTHTAX_DISEASE_DISEASESWB_1406_DISEASESWB_621_HEALTH_NUTRITION_AND_POPULATION
Topic context
This topic has been covered 342769 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAltimmune (NASDAQ:ALT) reported a narrower-than-expected Q1 loss and strong cash position, funding upcoming Phase 3 trial for pemvidutide in MASH. The stock rose ~3% premarket. Commercial mechanism is weak: no revenue, no partnership, no regulatory catalyst yet. Impact is single-company-specific, limited to biotech sector.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Altimmune Q1 2026 net loss $22.6M vs $19.6M prior year
- EPS -$0.18 beats consensus -$0.24
- Cash and investments $535M as of April 30, 2026
- Completed $225M public offering
- PERFORMA Phase 3 MASH trial to launch H2 2026; RECLAIM Phase 2 AUD topline Q3 2026
